Protara Therapeutics (TARA) Operating Expenses (2013 - 2026)

Over the trailing twelve months to Jun 30, 2026, Protara Therapeutics reported Operating Expenses of $76.79 million, up 33.9% year-over-year; for FY2025, it came in at $64.55 million, up 31.3% from FY2024.

• Operating Expenses carries a five-year compound annual growth rate of 13.4% (FY2020 to FY2025).
• Going back by year, Operating Expenses was $49.15 million in FY2024 (+12.7%), $43.61 million in FY2023 (-35.0%), $67.06 million in FY2022 (+41.2%) and $47.49 million in FY2021 (+37.9%).
• The Q2 2026 figure represents the highest quarterly Operating Expenses since Q4 2022.
• Year-over-year, Operating Expenses has increased for eight consecutive quarters, with growth averaging 31.5% over the last eight quarters.
• The fastest year-over-year change in Operating Expenses over five years came in Q4 2022 (growth of 284.1%), and the weakest in Q4 2023 (a decline of 72.1%).
• Business Quant data shows TARA's Operating Expenses at $19.63 million (Q1 2026), $19.08 million (Q4 2025) and $14.76 million (Q3 2025) in the three quarters before Q2 2026.